Clinical trial NCT05441826: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Official title: A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Minimal Change Disease
Focal Segmental Glomerulosclerosis
Lead sponsor: Tenet Medicines
Sponsor class: INDUSTRY
First posted: 2022-07-01
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid therapy.


Eligibility criteria: Inclusion Criteria:

1. Is ≥ 18 years of age at the time of informed consent;
2. Kidney biopsy-proven diagnosis of primary MCD or primary FSGS within the past 10 years. Subjects with kidney biopsy-proven diagnosis of primary MCD or primary FSGS greater than 10 years and less than 20 years prior to Screening who meet all other eligibility criteria may be enrolled after discussion with the Medical Monitor
3. History of steroid-sensitive MCD or FSGS, defined as having achieved complete remission of proteinuria (reduction of proteinuria to \<0.5 g/g UPCR) after use of corticosteroids;
4. Has experienced meaningful proteinuria in the last 2 years prior to Screening, defined as UPCR \>2.0 g/g, after attempted or completed tapering of steroids and/or CNIs that occurs within 6 months of the attempt or completion of tapering;
5. Currently on prednisone regimen at time of Screening and anticipated to be tapered to a stable dose of prednisone of no more than 20 mg/day for at least 14 days prior to Day 1
6. Has systolic blood pressure (BP) \<160 mmHg or diastolic BP \<100 mmHg after 5 minutes of rest at Screening;
7. Is willing and able to provide written informed consent prior to Screening;
8. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone in the postmenopausal range at Screening, based on the central laboratory's ranges;
9. Female subjects of childbearing potential (ie, ovulating, premenopausal, or not surgically sterile) and all male subjects must use a medically accepted, highly effective contraceptive regimen during their participation in the study and for 125 days (4 months) after the last administration of study drug.
10. Male subjects must agree to abstain from sperm donation through 125 days (4 months) after administration of the last dose of study drug.

Exclusion Criteria:

1. Has an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 at Screening utilizing the Chronic Kidney DiseaseEpidemiology Collaboration formula confirmed by the central laboratory;
2. Has an absolute neutrophil count \<1.5 x 10/L;
3. Has a white blood cell count \<3.0 x 10/L;
4. Has secondary causes of MCD or FSGS (eg, malignancy, hepatitis B or C, human immunodeficiency virus \[HIV\], systemic lupus erythematosus \[SLE\], or other autoimmune diseases \[eg, thyroiditis\], drug-induced);
5. Has a diagnosis or history of SLE (including non renal disease);
6. Has type 1 or 2 diabetes mellitus;
7. Has an acute, chronic, or latent infection, including tuberculosis, hepatitis, HIV, or chronic urinary tract infection.

Primary outcomes:
measure: The proportion of subjects in remission at End of Treatment
timeFrame: Day 274
measure: Incidence of serious adverse events (SAEs)
timeFrame: through Day 420
measure: Incidence of treatment-emergent adverse events (TEAEs)
timeFrame: through Day 420
measure: Incidence of adverse events of special interest (AESIs)
timeFrame: through Day 420
Secondary outcomes:
measure: Change in UPCR
timeFrame: Multiple timepoints from Day 1 to Day 337
measure: Change in eGFR
timeFrame: Multiple timepoints from Screening to Day 337
measure: Proportion of subjects that are recurrence-free
timeFrame: From Day 1 to Day 337
Other outcomes:
Locations:
city: Albany
country: United States
facility: Clinical Research Site
state: New York
Study officials:
affiliation: ValenzaBio, Inc.
name: Keenan
role: STUDY_CHAIR
References: